| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 30.06 | 21 |
| Intrinsic value (DCF) | 5.68 | -77 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Mirion Technologies, Inc. (NYSE: MIR) is a global leader in radiation detection, measurement, and monitoring solutions, serving critical industries such as healthcare, nuclear energy, and defense. Headquartered in Atlanta, Georgia, Mirion operates through two key segments: Medical and Industrial. The Medical segment provides radiation oncology quality assurance, patient safety solutions, and radionuclide therapy products, supporting cancer treatment, diagnostics, and practitioner safety. The Industrial segment delivers radiation safety and measurement tools for nuclear power plants, military applications, and industrial settings. With a diversified product portfolio—including dosimeters, contamination monitors, and reactor instrumentation—Mirion serves hospitals, government agencies, and utility companies worldwide. The company’s expertise in radiation technology positions it as a vital player in industries where safety and precision are paramount. Despite recent net losses, Mirion’s strong cash flow and niche market focus underscore its resilience in a specialized industrial machinery sector.
Mirion Technologies presents a mixed investment profile. The company operates in a high-barrier niche with strong demand for radiation safety solutions, particularly in nuclear energy and healthcare. Its diversified revenue streams and global footprint (spanning the U.S., Europe, and Asia) mitigate regional risks. However, investors should note its recent net losses ($36.1M in FY 2023) and diluted EPS of -$0.18, though operating cash flow remains positive ($99.1M). The low beta (0.74) suggests relative stability compared to broader markets, but debt levels ($719.9M) warrant monitoring. Growth potential lies in expanding nuclear power infrastructure and advancements in radiation therapy, though competition and R&D costs could pressure margins. A lack of dividends may deter income-focused investors.
Mirion Technologies holds a defensible position in the radiation detection market due to its specialized expertise and broad product suite. Its dual-segment approach (Medical/Industrial) diversifies revenue while leveraging cross-industry technological synergies. In the Medical segment, Mirion competes on precision and regulatory compliance, critical for oncology and diagnostic applications. The Industrial segment benefits from long-term contracts with nuclear facilities and governments, creating recurring revenue. However, the company faces pricing pressure from low-cost manufacturers in Asia and innovation-driven rivals in medical technology. Mirion’s competitive edge lies in its integrated solutions (hardware + software) and regulatory certifications, which are costly for new entrants to replicate. Its $4.25B market cap reflects moderate scale compared to larger industrials, but niche focus limits exposure to macroeconomic downturns. Key risks include reliance on government spending (especially defense) and slower adoption of nuclear energy in some regions.